IRD

Opus Genetics, Inc. Common Stock (IRD) | Rumor.io

Opus Genetics

IRD

Attention (50-day avg)0%

Attention rank (50-day avg)#1,399

Bullish sentiment (50-day avg)95%

Price to earnings ratio-6.34

Market capitalization420.1M

Earnings per share-1.29

Dividend yield (TTM)—

Revenue (annual)14.2M

Net income (annual)-49.6M

Social

What share of all stock conversation is about IRD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 11

The FDA PDUFA goal date for Opus Genetics (Nasdaq: IRD) is October 17, 2026, with a potential stock price near 10 bucks before this date.
Opus Genetics corrected an error in its clinical data presentation, revealing a 12-letter improvement for patients in its Phase 1/2 trial.
A consolidation above $7 could lead to a stock price near 10 bucks before the PDUFA goal date, with a potential break and hold above this level.

Generated by AI

Sentiment

Of the messages about IRD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	95.43% -4.57	95.74% +10.95
Bearish	—	—	4.57% +4.57	4.26% -10.95

Bullish· Sep 10

Opus Genetics, Inc. (IRD) has received two price target raises this week, one from Oppenheimer and another from Andreas Argyrides (Chardan Capital).
The company has delivered on its catalyst, with all 5 patients in the low-dose OPGx-BEST1 cohort showing clinically meaningful improvement in at least one visual-function.
IRD has broken out of its recent range, with price now well above key moving averages and volume clearly confirming the move, making $5.50 an important area to hold.

Bearish· Jun 2

IRD's price dropped from $2.30 to $1.17 pre-market, with some investors expecting further decline.
The asset's volume is unusually high, with 32 million shares traded on a day with little gain, suggesting heavy selling pressure.
IRD's price action may be influenced by market manipulators, with some investors suggesting that the company and its market makers are working together to drive down the price.

Generated by AI

Topics

Of the messages about IRD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	62.39%	54.83%
Technical Analysis	—	—	10.09%	11.58%
Analysts	—	—	27.52%	33.59%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Jun 2

Opus Genetics, Inc. (IRD) announced positive results from the LYNX-2 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% for keratorefractive patients with visual disturbances.
The trial met its primary endpoint, with 17.3% of patients treated with Phentolamine Ophthalmic Solution 0.75% achieving a greater than or equal to 15-letter Early Treatment Diabetic Retinopathy Study improvement in Mesopic Low Contrast Distance Visual Acuity at Day 15.
Opus Genetics shares are trading higher, up 19% on the PRISM Emerging Pharmaceutical Index, following the announcement of the successful Phase 3 trial results.

Macro· Oct 28

The Interest Rate Differential (IRD) penalty applies when fixed-rate mortgage holders break their contract to take advantage of lower rates, resulting in a true-up to the lender on the interest they "missed out on" during the term.
The IRD penalty is typically more significant than the 3-month interest penalty, making it a crucial consideration for mortgage holders in a declining interest rate environment.
In a falling rate environment, mortgage holders may want to consider breaking their fixed-rate mortgage and taking on a variable rate to avoid the IRD penalty, but this decision should be made quickly to minimize the impact.

Generated by AI

Community

Of the messages about IRD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	21.21%	33.65%
Newcomers	—	100%	78.79%	66.35%

Regulars· Sep 9

Opus Genetics reported positive low-dose Cohort 1 data for OPGx-BEST1 and had a successful FDA Type C meeting, supporting potential Phase 3 dosing in 2027.
The company's early OPGx-BEST1 data, FDA endpoint alignment, and 2029 cash runway are key factors supporting Opus Genetics.
The company's recent FDA agreement on a lower decibel change for upcoming trials is a major positive change, according to Mark Pennesi, M.D., Ph.D.

Newcomers· Sep 11

The newcomer is watching Opus Genetics, Inc. ($IRD) for potential catalysts in the near term.
The newcomer is considering buying $IRD on any pullback, with a target of $6.44 and potential extension to $6.90-$6.98.
The newcomer believes Opus Genetics, Inc. ($IRD) has potential for continuation, with a focus on the upcoming data read on October 4 and the stock's recent movement.

Generated by AI

Opus Genetics, Inc. (NASDAQ:IRD) reported on September 9 that all five low-dose BIRD-1 participants showed clinically meaningful improvement on at least one visual-function measure after treatment with investigational gene therapy OPGx-BEST1. The open-label Phase 1/2 cohort included three participants with Best vitelliform macular dystrophy followed for three months and two with autosomal recessive bestrophinopathy followed […]

13d agoYahoo Finance

NEWSLETTER: Experimental eye drops ease night vision problems for drivers

19d agoReuters

Opus Genetics: A Resounding Study Success Merits A Higher Valuation (NASDAQ:IRD)

19d agoSeeking Alpha

Chardan Raises Price Target on Opus Genetics to $16 From $13, Keeps Buy Rating

Opus Genetics (IRD) has an average rating of buy and mean price target of $13, according to analysts

20d agoYahoo Finance

Wedbush Raises Price Target on Opus Genetics to $13 From $10, Keeps Outperform Rating

Opus Genetics (IRD) has an average rating of buy and mean price target of $13, according to analysts

20d agoYahoo Finance

Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial - Slideshow

20d agoSeeking Alpha

Also Discussed

Investors talking about IRD also mention

#	Name	Attention
1	BioAffinity Technologies Inc.BIAF	0%+0
2	Tenon Medical, Inc.TNON	0%new
3	Firefly Neuroscience IncAIFF	0%-0.01
4	Brown Advisory Sustainable Value ETFBASV	0%0
5	Direxion Daily BA Bull 2X ETFBOEU	0%0
6	JPMorgan Healthcare Leaders ETFJDOC	0%0
7	Brookfield Property Partners LPBPYPN	0%0
8	Defiance Daily Target 2X Short SMCI ETFSMCZ	0%0
9	Themes ETF Trust - Leverage Shares 2X Long ARM Daily ETFARMG	0%0
10	Donegal Group Inc. Class A Common StockDGICA	0%0

Opus Genetics, Inc. Common Stock

Healthcare
Biotechnology

Opus Genetics, Inc. Common Stock represents an equity interest in Opus Genetics, a clinical-stage biopharmaceutical company focused on ophthalmic therapies. The company develops gene therapies for inherited retinal diseases and additional small-molecule treatments for other eye disorders, including programs aimed at retinal degeneration, refractive conditions, and other vision-related diseases. Its current pipeline includes investigational candidates such as OPGx-LCA5 and OPGx-BEST1, along with other ophthalmology-focused programs targeting specific genetic retinal conditions. Opus Genetics serves the broader vision-care market through research, development, and commercialization efforts centered on restoring or preserving sight in patients with unmet medical needs. The company is headquartered in Durham, North Carolina.

Website

Location

8 Davis Drive

Durham, NC, 27713

United States

Social

What share of all stock conversation is about IRD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 11

The FDA PDUFA goal date for Opus Genetics (Nasdaq: IRD) is October 17, 2026, with a potential stock price near 10 bucks before this date.
Opus Genetics corrected an error in its clinical data presentation, revealing a 12-letter improvement for patients in its Phase 1/2 trial.
A consolidation above $7 could lead to a stock price near 10 bucks before the PDUFA goal date, with a potential break and hold above this level.

Generated by AI

Sentiment

Of the messages about IRD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	95.43% -4.57	95.74% +10.95
Bearish	—	—	4.57% +4.57	4.26% -10.95

Bullish· Sep 10

Opus Genetics, Inc. (IRD) has received two price target raises this week, one from Oppenheimer and another from Andreas Argyrides (Chardan Capital).
The company has delivered on its catalyst, with all 5 patients in the low-dose OPGx-BEST1 cohort showing clinically meaningful improvement in at least one visual-function.
IRD has broken out of its recent range, with price now well above key moving averages and volume clearly confirming the move, making $5.50 an important area to hold.

Bearish· Jun 2

IRD's price dropped from $2.30 to $1.17 pre-market, with some investors expecting further decline.
The asset's volume is unusually high, with 32 million shares traded on a day with little gain, suggesting heavy selling pressure.
IRD's price action may be influenced by market manipulators, with some investors suggesting that the company and its market makers are working together to drive down the price.

Generated by AI

Topics

Of the messages about IRD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	62.39%	54.83%
Technical Analysis	—	—	10.09%	11.58%
Analysts	—	—	27.52%	33.59%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Jun 2

Opus Genetics, Inc. (IRD) announced positive results from the LYNX-2 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% for keratorefractive patients with visual disturbances.
The trial met its primary endpoint, with 17.3% of patients treated with Phentolamine Ophthalmic Solution 0.75% achieving a greater than or equal to 15-letter Early Treatment Diabetic Retinopathy Study improvement in Mesopic Low Contrast Distance Visual Acuity at Day 15.
Opus Genetics shares are trading higher, up 19% on the PRISM Emerging Pharmaceutical Index, following the announcement of the successful Phase 3 trial results.

Macro· Oct 28

The Interest Rate Differential (IRD) penalty applies when fixed-rate mortgage holders break their contract to take advantage of lower rates, resulting in a true-up to the lender on the interest they "missed out on" during the term.
The IRD penalty is typically more significant than the 3-month interest penalty, making it a crucial consideration for mortgage holders in a declining interest rate environment.
In a falling rate environment, mortgage holders may want to consider breaking their fixed-rate mortgage and taking on a variable rate to avoid the IRD penalty, but this decision should be made quickly to minimize the impact.

Generated by AI

Community

Of the messages about IRD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	21.21%	33.65%
Newcomers	—	100%	78.79%	66.35%

Regulars· Sep 9

Opus Genetics reported positive low-dose Cohort 1 data for OPGx-BEST1 and had a successful FDA Type C meeting, supporting potential Phase 3 dosing in 2027.
The company's early OPGx-BEST1 data, FDA endpoint alignment, and 2029 cash runway are key factors supporting Opus Genetics.
The company's recent FDA agreement on a lower decibel change for upcoming trials is a major positive change, according to Mark Pennesi, M.D., Ph.D.

Newcomers· Sep 11

The newcomer is watching Opus Genetics, Inc. ($IRD) for potential catalysts in the near term.
The newcomer is considering buying $IRD on any pullback, with a target of $6.44 and potential extension to $6.90-$6.98.
The newcomer believes Opus Genetics, Inc. ($IRD) has potential for continuation, with a focus on the upcoming data read on October 4 and the stock's recent movement.

Generated by AI

Opus Genetics

Social

Sep 11

Bullish· Sep 10

Bearish· Jun 2

Announcements· Jun 2

Macro· Oct 28

Regulars· Sep 9

Newcomers· Sep 11

Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?

NEWSLETTER: Experimental eye drops ease night vision problems for drivers

Opus Genetics: A Resounding Study Success Merits A Higher Valuation (NASDAQ:IRD)

Chardan Raises Price Target on Opus Genetics to $16 From $13, Keeps Buy Rating

Wedbush Raises Price Target on Opus Genetics to $13 From $10, Keeps Outperform Rating

Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial - Slideshow

Also Discussed

Opus Genetics, Inc. Common Stock

Company Information

Location

Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?

NEWSLETTER: Experimental eye drops ease night vision problems for drivers

Opus Genetics: A Resounding Study Success Merits A Higher Valuation (NASDAQ:IRD)

Chardan Raises Price Target on Opus Genetics to $16 From $13, Keeps Buy Rating

Wedbush Raises Price Target on Opus Genetics to $13 From $10, Keeps Outperform Rating

Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial - Slideshow

Also Discussed

Social

Sep 11

Bullish· Sep 10

Bearish· Jun 2

Announcements· Jun 2

Macro· Oct 28

Regulars· Sep 9

Newcomers· Sep 11